Unlearn.AI

“What sets our model apart is how we’ve tailored our approach to predicting disease progression over time...Our models are specifically designed to predict changes in disease, utilizing novel architectures that are well-suited for this purpose…By offering these advanced AI-driven models, we provide our clients with a broader lens through which they can view their clinical research, enabling insights that might otherwise be inaccessible.” – Steven Herne Thanks to NeurologyLive and Marco Meglio for featuring Unlearn 🚀 Read now: https://lnkd.in/gepwrCek

“If we really want #AI to have an impact on #drugdevelopment, we’re going to need to invite more AI researchers into the drug development process.” - Charles Fisher at the FDA/Clinical Trials Transformation Initiative (CTTI) workshop, ‘AI in Drug & Biological Product Development.’ Watch the recording here: https://lnkd.in/gyhqUBgD 🚀

Participants’ #digitaltwins can cut control arm sizes by up to 33% in Alzheimer’s disease #clinicaltrials, allowing more patients to receive the experimental treatment while helping to accelerate the development of new treatments. 🚀 Thanks to Brian K. Buntz and Drug Discovery & Development for featuring our founder and CEO, Charles Fisher. https://lnkd.in/gs8kspQW

🌐 According to the World Health Organization, major depressive disorder impacts approximately 280 million people globally, while schizophrenia affects about 24 million. To accelerate #clinicaldevelopment and bring new treatments to patients faster, we launched #DigitalTwin Generators for both #schizophrenia and #majordepressivedisorder last month. Explore them here: https://lnkd.in/ghYgWZxv

🔬 Clinical studies are large, costly, and slow to enroll. We have the solution.

#UnlearnerSpotlight 🚀 Ginny H. Role: “I design the software that brings digital twins to life, helping pharma and biotech companies gain deeper insights into their clinical trials, enabling them to make more informed decisions.” Favorite part about working at Unlearn: “We’re the pioneers of digital twins and tackle some of the toughest challenges in medicine. Being surrounded by such talented and passionate colleagues keeps me inspired. We push each other to innovate and excel. At Unlearn, we value great user experiences, ensuring that our groundbreaking technology is both powerful and intuitive. It’s fulfilling to know that my design contributions have a meaningful impact on healthcare.”

Thanks to Nicole Deslandes and TechInformed for featuring our founder and CEO, Charles Fisher 🚀 Read now: https://lnkd.in/g8Pj5hei

💬 There's been significant discussion around the #FDA and #AI regulation lately. #ICYMI: Our Senior Government Affairs Lead, Jess Ross, wrote an article in MedCity News on driving #clinicaltrial innovation through AI #regulation at the FDA. The piece highlights the FDA’s crucial role in balancing innovation with safety and responsibility. https://bit.ly/3X3Ao95

📣 We’ve only begun to scratch the surface of realizing AI’s full potential in #medicine. Hear from Charles Fisher, CEO and founder of Unlearn, as he discusses AI’s growing role in #healthcare, highlights its current applications, and envisions the groundbreaking possibilities that lie ahead. https://lnkd.in/gT4BQwe9

Check out the key findings from our #AAIC24 poster with Johnson & Johnson Innovative Medicine ⬇